These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19498185)

  • 1. Treating patients with ischemic stroke with tissue plasminogen activator in the 3.5- to 4-hour window: numbers support benefit but the message is to still go fast.
    Kurth T; Tzourio C
    Stroke; 2009 Jul; 40(7):2295-6. PubMed ID: 19498185
    [No Abstract]   [Full Text] [Related]  

  • 2. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
    Wechsler LR
    Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061
    [No Abstract]   [Full Text] [Related]  

  • 3. 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.
    Schellinger PD; Köhrmann M
    Stroke; 2014 Mar; 45(3):912-3. PubMed ID: 24526060
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombolysis in the 3- to 4.5-hour window: what do ECASSkeptics want?
    Selim MH; Molina CA
    Stroke; 2014 Mar; 45(3):916-7. PubMed ID: 24526059
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.
    Wechsler LR; Jovin TG
    Stroke; 2012 Sep; 43(9):2517-9. PubMed ID: 22910892
    [No Abstract]   [Full Text] [Related]  

  • 6. Intraarterial thrombolysis within the first three hours after acute ischemic stroke in selected patients.
    Moonis M
    Stroke; 2009 Jul; 40(7):2611-2. PubMed ID: 19443796
    [No Abstract]   [Full Text] [Related]  

  • 7. Is intraarterial tPA within 3 hours the treatment of choice for selected stroke patients?: No.
    Lindley RI
    Stroke; 2009 Jul; 40(7):2613-4. PubMed ID: 19443793
    [No Abstract]   [Full Text] [Related]  

  • 8. IV and IA thrombolytic stroke strategies are complementary.
    Donnan GA; Davis SM
    Stroke; 2009 Jul; 40(7):2615. PubMed ID: 19443794
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
    Leiva-Salinas C; Patrie JT; Xin W; Michel P; Jovin T; Wintermark M
    Stroke; 2016 Feb; 47(2):397-403. PubMed ID: 26696647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Cooperative Acute Stroke Study III: support for and questions about a truly emerging therapy.
    Fisher M; Hachinski V
    Stroke; 2009 Jun; 40(6):2262-3. PubMed ID: 19390068
    [No Abstract]   [Full Text] [Related]  

  • 13. Pro: intravenous tissue plasminogen activator in stroke patients with rapid, complete recovery during evaluation (transient ischemic attack) and evidence of middle cerebral artery occlusion.
    Köhrmann M; Schellinger PD
    Stroke; 2010 Dec; 41(12):3003-4. PubMed ID: 21030698
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolysis, community hospitals, and primary stroke center.
    Jeng JS
    Acta Neurol Taiwan; 2009 Mar; 18(1):1-2. PubMed ID: 19537567
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical therapy for ischemic stroke: review of intravenous and intra-arterial treatment options.
    Taussky P; Tawk RG; Daugherty WP; Hanel RA
    World Neurosurg; 2011 Dec; 76(6 Suppl):S9-15. PubMed ID: 22182278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
    Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
    Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA.
    Ghandehari K; Zahed AP; Taheri M; Abbasi M; Gorjestani S; Ahmadi AM; Nahayati MA
    Int J Stroke; 2009 Aug; 4(4):236. PubMed ID: 19689746
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.
    ; Brown MD; Burton JH; Nazarian DJ; Promes SB
    Ann Emerg Med; 2015 Sep; 66(3):322-333.e31. PubMed ID: 26304253
    [No Abstract]   [Full Text] [Related]  

  • 19. When is enough enough?
    Donnan GA; Davis SM
    Stroke; 2001 Nov; 32(11):2710-1. PubMed ID: 11692042
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of good clinical outcome in acute stroke patients treated with intravenous thrombolysis.
    Saňák D; Herzig R; Zapletalová J; Horák D; Král M; Skoloudík D; Bártková A; Veverka T; Heřman M; Kaňovský P
    Acta Neurol Scand; 2011 May; 123(5):339-44. PubMed ID: 20597864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.